Pyxis Oncology Presents New Data Showing MICVO Effective in Head and Neck Cancer Model
Pyxis Oncology announced that it will present new preclinical data highlighting that a mouse analogue of MICVO demonstrates anti-tumor activity in a preclinical head and neck squamous cell carcinoma model as monotherapy, and synergistic anti-tumor activity in combination with anti-mouse PD-1. These data will be presented in a poster session at the American Association for Cancer Research Annual Meeting 2026 in San Diego, California, held April 17 - April 22. "These new preclinical data are particularly compelling as they further reinforce MICVO's clinical development in HNSCC, both as a novel monotherapy treatment and in combination with anti-PD-1," said Tom Civik, interim CEO of Pyxis Oncology. "An important finding from the data is that combination treatment with maMICVO and anti-mouse PD-1 demonstrated synergistic anti-tumor activity and greater tumor control than either treatment alone in an immunotherapy-refractory preclinical HNSCC model, highlighting MICVO's novel three-pronged mechanism of action and its potential to meaningfully enhance response to immunotherapy. Following our mid-year 2026 MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC, we look forward to sharing updated data from the ongoing Phase 1/2 combination dose escalation study of MICVO in combination with pembrolizumab for 1L/2L+ R/M HNSCC patients in the second half of 2026."
